Clopidogrel/Acetylsalicylic acid Teva

Nazione: Unione Europea

Lingua: inglese

Fonte: EMA (European Medicines Agency)

Compra

Foglio illustrativo Foglio illustrativo (PIL)
28-04-2017
Scheda tecnica Scheda tecnica (SPC)
28-04-2017

Principio attivo:

clopidogrel, Acetylsalicylic acid

Commercializzato da:

Teva Pharma B.V.

Codice ATC:

B01AC30

INN (Nome Internazionale):

clopidogrel, acetylsalicylic acid

Gruppo terapeutico:

combinations

Area terapeutica:

Acute Coronary Syndrome; Myocardial Infarction

Indicazioni terapeutiche:

Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). Clopidogrel/Acetylsalicylic acid Teva is a fixed‑dose combination medicinal product for continuation of therapy in:Non‑ST segment elevation acute coronary syndrome (unstable angina or non‑Q‑wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary interventionST segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy

Dettagli prodotto:

Revision: 1

Stato dell'autorizzazione:

Withdrawn

Data dell'autorizzazione:

2014-09-01

Foglio illustrativo

                                59
B. PACKAGE LEAFLET
Medicinal product no longer authorised
60
PACKAGE LEAFLET: INFORMATION FOR THE USER
CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA 75 MG/75 MG FILM-COATED TABLETS
clopidogrel/acetylsalicylic acid
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4. .
WHAT IS IN THIS LEAFLET
1.
What Clopidogrel/Acetylsalicylic acid Teva is and what it is used for
2.
What you need to know before you take Clopidogrel/Acetylsalicylic acid
Teva
3.
How to take Clopidogrel/Acetylsalicylic acid Teva
4.
Possible side effects
5.
How to store Clopidogrel/Acetylsalicylic acid Teva
6.
Contents of the pack and other information
1.
WHAT CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA IS AND WHAT IT IS USED FOR
Clopidogrel/Acetylsalicylic acid Teva contains clopidogrel and
acetylsalicylic acid (ASA) and belongs
to a group of medicines called antiplatelet medicinal products.
Platelets are very small structures in the
blood which clump together during blood clotting. By preventing this
clumping in some types of blood
vessels (called arteries), antiplatelet medicinal products reduce the
chances of blood clots forming (a
process called atherothrombosis).
Clopidogrel/Acetylsalicylic acid Teva is taken by adults to prevent
blood clots forming in hardened
arteries which can lead to atherothrombotic events (such as stroke,
heart attack, or death).
You have been prescribed Clopidogrel/Acetylsalicylic acid Teva in
place of the two separate
medicines, clopidogrel and ASA, to help prevent blood clots because
you have experienced a severe
type of chest pain known as ‘unst
                                
                                Leggi il documento completo
                                
                            

Scheda tecnica

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Clopidogrel/Acetylsalicylic acid Teva 75 mg/75 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen
sulphate) and 75 mg of
acetylsalicylic acid (ASA).
Excipient with known effect:
Each film-coated tablet contains 102.6 mg of lactose (as lactose
monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet)
Yellow, film-coated capsule shaped tablets. The tablets have a length
of 14.0 mm and a width of
6.8 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Clopidogrel/Acetylsalicylic acid Teva is indicated for the prevention
of atherothrombotic events in
adult patients already taking both clopidogrel and acetylsalicylic
acid (ASA).
Clopidogrel/Acetylsalicylic acid Teva is a fixed-dose combination
medicinal product for continuation
of therapy in:

Non-ST segment elevation acute coronary syndrome (unstable angina or
non-Q-wave
myocardial infarction) including patients undergoing a stent placement
following percutaneous
coronary intervention

ST segment elevation acute myocardial infarction in medically treated
patients eligible for
thrombolytic therapy
For further information please refer to section 5.1.
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_ _
Posology

Adults and elderly population
Clopidogrel/Acetylsalicylic acid Teva should be given as a single
daily 75 mg/75 mg dose.
Clopidogrel/Acetylsalicylic acid Teva is used following initiation of
therapy with clopidogrel and
ASA given separately.
-
_In patients with non-ST segment elevation acute coronary syndrome_
(unstable angina or
non-Q-wave myocardial infarction): The optimal duration of treatment
has not been formally
established. Clinical trial data support use up to 12 months, and the
maximum benefit was seen
at 3 months (see section 5.1). If the use of the combination of
clopidogrel/acetylsalic
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Foglio illustrativo Foglio illustrativo bulgaro 28-04-2017
Scheda tecnica Scheda tecnica bulgaro 28-04-2017
Foglio illustrativo Foglio illustrativo spagnolo 28-04-2017
Scheda tecnica Scheda tecnica spagnolo 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione spagnolo 28-04-2017
Foglio illustrativo Foglio illustrativo ceco 28-04-2017
Scheda tecnica Scheda tecnica ceco 28-04-2017
Foglio illustrativo Foglio illustrativo danese 28-04-2017
Scheda tecnica Scheda tecnica danese 28-04-2017
Foglio illustrativo Foglio illustrativo tedesco 28-04-2017
Scheda tecnica Scheda tecnica tedesco 28-04-2017
Foglio illustrativo Foglio illustrativo estone 28-04-2017
Scheda tecnica Scheda tecnica estone 28-04-2017
Foglio illustrativo Foglio illustrativo greco 28-04-2017
Scheda tecnica Scheda tecnica greco 28-04-2017
Foglio illustrativo Foglio illustrativo francese 28-04-2017
Scheda tecnica Scheda tecnica francese 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione francese 28-04-2017
Foglio illustrativo Foglio illustrativo italiano 28-04-2017
Scheda tecnica Scheda tecnica italiano 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione italiano 28-04-2017
Foglio illustrativo Foglio illustrativo lettone 28-04-2017
Scheda tecnica Scheda tecnica lettone 28-04-2017
Foglio illustrativo Foglio illustrativo lituano 28-04-2017
Scheda tecnica Scheda tecnica lituano 28-04-2017
Foglio illustrativo Foglio illustrativo ungherese 28-04-2017
Scheda tecnica Scheda tecnica ungherese 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione ungherese 28-04-2017
Foglio illustrativo Foglio illustrativo maltese 28-04-2017
Scheda tecnica Scheda tecnica maltese 28-04-2017
Foglio illustrativo Foglio illustrativo olandese 28-04-2017
Scheda tecnica Scheda tecnica olandese 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione olandese 28-04-2017
Foglio illustrativo Foglio illustrativo polacco 28-04-2017
Scheda tecnica Scheda tecnica polacco 28-04-2017
Foglio illustrativo Foglio illustrativo portoghese 28-04-2017
Scheda tecnica Scheda tecnica portoghese 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione portoghese 28-04-2017
Foglio illustrativo Foglio illustrativo rumeno 28-04-2017
Scheda tecnica Scheda tecnica rumeno 28-04-2017
Foglio illustrativo Foglio illustrativo slovacco 28-04-2017
Scheda tecnica Scheda tecnica slovacco 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione slovacco 28-04-2017
Foglio illustrativo Foglio illustrativo sloveno 28-04-2017
Scheda tecnica Scheda tecnica sloveno 28-04-2017
Foglio illustrativo Foglio illustrativo finlandese 28-04-2017
Scheda tecnica Scheda tecnica finlandese 28-04-2017
Relazione pubblica di valutazione Relazione pubblica di valutazione finlandese 28-04-2017
Foglio illustrativo Foglio illustrativo svedese 28-04-2017
Scheda tecnica Scheda tecnica svedese 28-04-2017
Foglio illustrativo Foglio illustrativo norvegese 28-04-2017
Scheda tecnica Scheda tecnica norvegese 28-04-2017
Foglio illustrativo Foglio illustrativo islandese 28-04-2017
Scheda tecnica Scheda tecnica islandese 28-04-2017
Foglio illustrativo Foglio illustrativo croato 28-04-2017
Scheda tecnica Scheda tecnica croato 28-04-2017